Your browser doesn't support javascript.
A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir.
Liang, Chengyuan; Tian, Lei; Liu, Yuzhi; Hui, Nan; Qiao, Guaiping; Li, Han; Shi, Zhenfeng; Tang, Yonghong; Zhang, Dezhu; Xie, Xiaolin; Zhao, Xu.
  • Liang C; School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China. Electronic address: chengyuanliang@gmail.com.
  • Tian L; School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Liu Y; School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Hui N; School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Qiao G; School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Li H; School of Food and Bioengineering, Shaanxi University of Science & Technology, Xi'an, 710021, PR China.
  • Shi Z; Department of Urology Surgery Center, The People's Hospital of Xinjiang Uyghur Autonomous Region, Urumqi, 830002, PR China.
  • Tang Y; Xi'an Taikomed Pharmaceutical Technology Co., Ltd., Xi'an, 710077, PR China.
  • Zhang D; Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China.
  • Xie X; Shaanxi Panlong Pharmaceutical Group Co., Ltd., Xi'an, 710025, PR China.
  • Zhao X; Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, PR China. Electronic address: zhaoxush@163.com.
Eur J Med Chem ; 201: 112527, 2020 Sep 01.
Article in English | MEDLINE | ID: covidwho-548763
ABSTRACT
Remdesivir (GS-5734), a viral RNA-dependent RNA polymerase (RdRP) inhibitor that can be used to treat a variety of RNA virus infections, is expected to be an effective treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On May 1, 2020, The U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients. In light of the COVID-19 pandemic, this review presents comprehensive information on remdesivir, including information regarding the milestones, intellectual properties, anti-coronavirus mechanisms, preclinical research and clinical trials, and in particular, the chemical synthesis, pharmacology, toxicology, pharmacodynamics and pharmacokinetics of remdesivir. Furthermore, perspectives regarding the use of remdesivir for the treatment of COVID-19 are also discussed.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Adenosine Monophosphate / Coronavirus Infections / Alanine / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Eur J Med Chem Year: 2020 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pneumonia, Viral / Adenosine Monophosphate / Coronavirus Infections / Alanine / Betacoronavirus Type of study: Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Eur J Med Chem Year: 2020 Document Type: Article